|
Mice
treated with anti-CD25 mAbs and live B16F10 can resist a second
challenge with B16F10a.
|
Treatment
|
Tumour-Free
Mice / Total
|
|
None
|
0/10
|
|
Anti-CD25 mAbs alone
|
0/10
|
|
Anti-CD25 mAbs
+ B16F10
|
10/14
|
aApproximately 8 wks after rejection of B16F10, B6
mice were re-challenged with 2 x 104 B16F10 cells.
As controls, mice that had received either anti-CD25 mAbs alone
or mice that had been left untreated were also challenged with
tumour cells.
|
